Hundreds of millions of people have been impacted by the COVID-19 pandemic with nearly 3 millions deaths since the 2019 outbreak began. Testing plays a crucial role in the containment and management of the COVID-19 pandemic by identifying infected individuals to help prevent further person-to-person transmission of COVID-19, as well as tracking and tracing outbreaks. Roche’s Global Access Program provides improved access to reliable and affordable high-throughput SARS-CoV-2 PCR testing for patients in low- and middle-income countries.
- Thomas Schinecker, Chief Executive Officer of Roche Diagnostics
Access to broader consolidated diagnostic solutions helps healthcare communities manage multiple disease burdens during a pandemic outbreak. Leveraging one instrument for a multitude of viral diseases enables large scale testing efficiency and alignment with country goals for integrated testing to support health system strengthening and pandemic readiness.
High-volume SARS-CoV-2 testing can be run simultaneously with other assays such as HIV-1 viral load and HIV-1/2 quantitative tests, in addition to Mycobacterium tuberculosis (MTB), hepatitis B and C (HBV and HCV) and human papillomavirus (HPV) for screening for cervical cancer.
Throughout the world there is intensive cooperation among industry, customers, nonprofits, governments and regulatory bodies to ensure we support where we can to contain the coronavirus. In these exceptional times, Roche stands shoulder to shoulder with governments, healthcare providers and all those working to overcome the pandemic.